Henry Schein (NASDAQ:HSIC – Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 5.420-5.480 for the period, compared to the consensus EPS estimate of 5.540. The company issued revenue guidance of $13.8 billion-$13.9 billion, compared to the consensus revenue estimate of $13.8 billion.
Henry Schein Price Performance
Shares of NASDAQ HSIC opened at $86.22 on Monday. The company has a market cap of $9.53 billion, a PE ratio of 23.62, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87. The business’s 50 day moving average price is $85.91 and its two-hundred day moving average price is $81.54. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18. The company has a quick ratio of 0.76, a current ratio of 1.33 and a debt-to-equity ratio of 0.62.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.20. The company had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.48 billion. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The company’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 earnings per share. On average, analysts predict that Henry Schein will post 5.55 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on HSIC. Citigroup reiterated a “buy” rating and issued a $112.00 target price (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. UBS Group increased their price objective on Henry Schein from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. BTIG Research increased their price objective on shares of Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $93.57.
Read Our Latest Report on Henry Schein
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Read More
- Five stocks we like better than Henry Schein
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
